The UCSF Fetal Treatment Center, UCSF Center for Maternal-Fetal Precision Medicine, and UCSF Benioff Children's Hospital Oakland Thalassemia Center’s Northern California Comprehensive Thalassemia Center have established the first multidisciplinary center for Alpha Thalassemia Major. The program is designed to address the complex diagnostic, prenatal, intrauterine, and perinatal management issues affecting a family with an Alpha Thalassemia Major pregnancy. Maternal and fetal complications of an Alpha thalassemia pregnancy are common and can be serious.
Prevention of Alpha Thalassemia Major with genetic counseling has been widely accepted throughout the world, but some families are seeking alternative options. We are offering intrauterine transfusions for fetuses with Alpha Thalassemia Major.
There is growing experience with fetal therapy for alpha thalassemia. Fetuses treated with intrauterine transfusions throughout pregnancy starting at an early gestational age (18-25 weeks) can survive to birth with acceptable morbidity. After birth, the treatment options include bone marrow transplantation or continued chronic transfusions. In the future, we plan to offer in utero stem cell transplantation for this disease.
For more information regarding Alpha Thalassemia Major, fetal intervention, and our multidisciplinary center, please visit:
For more information about this treatment, or to refer a patient, please call 1-800-RX-FETUS (1-800-793-3887) or send us an email at email@example.com.